Monday, July 20, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jul 17, 2026
Chutes & Ladders—Cue lines up new CMO and research head
background ▾
- •Cue Biopharma hired experienced immunology executive Dominic Borie as CMO and R&D head; company expects phase 2 data for CUE-221 by Q3 2026
Cue BiopharmaProFound TherapeuticsElevara MedicinesCUE-221CUE-401ELV001
→ Read original articlePolicy•Fierce Biotech•Jul 20, 2026
Building a workforce engine for biomanufacturing
background ▾
- •Workforce availability has emerged as a critical constraint on biomanufacturing expansion in Ohio despite strong infrastructure (sites, utilities, power); operators and technicians are the primary gap.
- •The $30 million investment creates a 'one front door' model with standardized certifications and statewide coordination, positioning Ohio to compete for capital-intensive manufacturing projects.
- •Monitor whether this model generates measurable hiring outcomes and whether other states replicate similar workforce pipelines as competing bids for biomanufacturing facilities intensify.
JobsOhioOhio Life Sciences Association
→ Read original articlePolicy•STAT News•Jul 20, 2026
Opinion: It’s time to treat pandemics as threats to national security
background ▾
- •Framing pandemics as national security threats could drive structural reforms in U.S. pandemic defense, including elevated NSC role and intelligence community participation in biosurveillance
- •Covid-19 inflicted greater mortality (1.2M deaths 2020-2026) and economic damage than all U.S. wars combined, yet receives lower defensive priority than counterterrorism
- •Watch for potential White House reorganization of pandemic preparedness structures and funding decisions for the underfunded Office of Pandemic Preparedness and Response
Policy•STAT News•Jul 20, 2026
Opinion: My husband’s suicide shows there’s something very wrong with the U.S. insurance industry
background ▾
- •This is an opinion/advocacy piece, not a news report—it does not contain actionable pharmaceutical industry intelligence, clinical trial data, regulatory decisions, or market developments
Policy•Endpoints News•Jul 17, 2026
Midsize biotechs press White House to drop CMS pricing rules
background ▾
- •Midsize biotech sector is actively lobbying against pending CMS pricing rules through direct White House engagement
- •The initiative suggests industry concern that pricing regulations disproportionately affect smaller companies relative to large pharma
- •Watch for regulatory announcements from CMS/HHS and whether the White House signals willingness to modify or delay pending pricing rules
Market Access
Market Access•Fierce Biotech•Jul 20, 2026
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
background ▾
- •Eli Lilly's $2.8B acquisition of AtaiBeckley validates psychedelics as a legitimate pharma investment thesis and signals confidence in BPL-003's phase 2b efficacy data, likely triggering follow-on M&A from other majors.
- •Recent FDA actions—priority review vouchers for three psychedelics programs (April 2026) and finalized developer guidance (this month)—represent regulatory de-risking that reshapes investor calculus and could accelerate clinical development across the sector.
- •Watch for: (1) Compass Pathways' COMP360 psilocybin therapy FDA decision and 2H 2027 launch timeline; (2) additional big pharma acquisitions or in-licensing in psychedelics; (3) whether Lykos can rehabilitate MDMA-assisted therapy after its 2024 advisory committee rejection; (4) political/regulatory sentiment shifts post-Trump administration focus on mental health.
Eli LillyAtaiBeckleyLykosBPL-0035-MeO-DMTbretisilocin
→ Read original articleMarket Access•Fierce Biotech•Jul 19, 2026
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
background ▾
- •Latigo secured strong prior funding ($135M Series A, $150M Series B) and is now IPO-bound with $54.8M cash; the IPO proceeds will directly fund phase 3 trials for LTG-001 starting H2 2024 with 2027 readouts
- •LTG-001 is positioned as a competitive alternative to Vertex's Journax, with Latigo claiming superiority on efficacy, speed of onset, and safety profile, though these claims remain unvalidated in head-to-head trials
- •Watch for: Phase 3 trial initiation and enrollment trends in H2 2024, IPO pricing/valuation signals from the biotech IPO market, and whether Latigo demonstrates clinical differentiation versus Journax in post-surgical and chronic pain settings
Latigo BiotherapeuticsVertex PharmaceuticalsWestlake Village BioPartnersLTG-001LTG-321LTG-418
→ Read original articleMarket Access•Fierce Biotech•Jul 17, 2026
Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
background ▾
- •Jasper gains access to Kira's differentiated complement pipeline, headlined by KP-104 (vensobafusp alfa) in PNH and nephrology—positioned as a Fabhalta alternative with phase 2 readout due Q4 2025.
- •The merger values Jasper's equity holders at ~7% of the combined entity, signaling significant dilution but providing capital and clinical momentum after the briquilimab manufacturing disaster.
- •Watch for Q4 2025 phase 2 data on KP-104 and FDA pre-phase 3 meeting outcomes; also monitor whether briquilimab gains traction in SCID as a recovery narrative for Jasper's core asset.
Jasper TherapeuticsKira PharmaceuticalsMirador TherapeuticsbriquilimabKP-104vensobafusp alfa
→ Read original articleMarket Access•Fierce Biotech•Jul 17, 2026
Abbott Q2 led by strong device, diagnostic sales as it boosts profit forecast
background ▾
- •Diagnostics division surged 42% YoY, significantly outpacing device growth, demonstrating the Cologuard acquisition's immediate impact and momentum in cancer screening
- •Abbott's concentrated portfolio in chronic disease management (diabetes, cardiovascular, cancer) may insulate it from uninsured patient shifts, contrasting with HCA's negative guidance
- •Monitor H2 performance against raised guidance and whether ACA subsidy impacts materialize across the broader medtech sector in coming quarters
AbbottExact SciencesHCACologuard
→ Read original articleMarket Access•Fierce Biotech•Jul 17, 2026
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
background ▾
- •BlossomHill's lead asset BH-30643 targets a crowded EGFR-mutant NSCLC space dominated by $7+ billion-selling Tagrisso and other established competitors, presenting significant commercialization risk
- •The company's secondary asset BH-30236 targeting CLK kinase would be first-in-class if approved, offering differentiated positioning outside the crowded EGFR field
BlossomHill TherapeuticsAstraZenecaJohnson & JohnsonBH-30643BH-30236BH-501284
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 20, 2026
Why early de-risking is redefining the path to IND
background ▾
- •Early de-risking—identifying formulation, analytical, and molecule-selection risks before IND—is becoming a competitive requirement for biotech teams rather than an optional optimization
- •The strategic shift is from maximizing speed to maximizing decision-quality under resource constraints, reducing downstream delays that jeopardize funding rounds and investor confidence
Lonza
→ Read original articleClinical Trials•Endpoints News•Jul 18, 2026
Biogen’s mixed Alzheimer’s data; Two new startups launch; and more
background ▾
- •Biogen's Alzheimer's program delivered mixed clinical data, indicating ongoing challenges in validating efficacy in this indication
Biogen
→ Read original articleClinical Trials•Endpoints News•Jul 17, 2026
GSK plans large study to see if shingles vaccine can prevent dementia
background ▾
- •GSK is launching a large-scale study to test whether Shingrix vaccination prevents dementia, based on encouraging signals from retrospective health record analysis
- •A positive outcome could substantially expand Shingrix's addressable market and establish a new preventive indication with significant public health implications for aging populations
- •Critical uncertainties include trial design details, enrollment timeline, mechanism of action (if real), and whether observational associations reflect causation or confounding
GSKShingrix
→ Read original articleClinical Trials•Endpoints News•Jul 17, 2026
GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyout
background ▾
- •GSK has terminated Phase 3 development of the lead Bellus Health chronic cough candidate, undermining the primary rationale for the $2B acquisition
- •The late-stage program discontinuation indicates potential efficacy, safety, or commercial viability concerns emerged during Phase 3 execution
- •Watch for GSK's official disclosure of Phase 3 data/reasons for termination and whether remaining Bellus pipeline programs remain on track
GSKBellus Health
→ Read original article